Tag Archives: MRK stock research

Merck & Co (MRK) 25Q1 Update

Posted on June 20, 2025 by Stephen Percoco

25Q1 sales decreased 1.6% to $15.5 billion and were 2.0% below my estimate.  Excluding currency, sales rose 1%.  Sales gains in KEYTRUDA, WINREVAIR and Animal Health offset a 41% drop in GARDASIL sales, as a sharp drop in sales in … Continue reading →

Posted in Health Care, MRK | Tagged , , | Leave a comment

Merck & Co (MRK) 24Q4 Update

Posted on March 25, 2025 by Stephen Percoco

24Q4 sales rose 6.8% to $15.6 billion.  Excluding currency, sales rose 9%.  Once again, a high teens percentage gain in KEYTRUDA sales more than offset declining sales in most of the rest of the portfolio.  GAAP diluted EPS was $1.48, … Continue reading →

Posted in Health Care, MRK | Tagged , | Comments Off on Merck & Co (MRK) 24Q4 Update